MAXIS GBN upgrades OneClient portal for multinationals
MAXIS Global Benefits Network (MAXIS GBN) in October 2019 announced that its OneClient service now provides access to a new suite of interactive dashboards and web applications to help multinationals identify employee benefits spending and healthcare priorities that aid decision-making and cost management.
One of the key new features of the OneClient portal is an interactive pooling dashboard that allows multinational pooling clients to better understand their pool performance and make decisions for the future.
Data visualizations provide an easy-to-use snapshot of the pool, highlighting overall performance, premium and expenses distribution, loss ratio heatmaps, and results and reserves overviews among others.
The dashboard allows clients to filter and drill-down by country, product, and policy to gain a deeper understanding of performance drivers.
The new version of the portal also includes a new tool, MAXIS WIT (Wellness Intelligence Tool), which uses medical claims data and actuarial calculations to help organizations calculate potential medical cost savings by implementing workplace wellness programs. MAXIS WIT will be launched to all captive clients in the next two weeks.
The new portal also includes improvements to health and wellness reporting provided by MAXIS GBN. The Paid Claims and Country Benchmark reports, a part of the health and wellness suite, are now interactive with easy-to-digest data visualizations.
This format gives E.B. decision-makers a clearer view of their medical spending in order to understand the areas they should target with wellness campaigns to help lower costs and improve overall employee health.
Multinationals can also access the Population Health and Risk Stratification report. Launched in July 2019, the report allows multinationals to categorize the severity of health risks their employees and dependents face to better understand health management practices.
It also enables them to initiate programs that help prevent chronic diseases, stabilize current chronic conditions and prevent an acceleration to higher-risk categories and higher associated costs.